### **KeyBanc Industrials & Basic Materials Conference**

June 2, 2022



### **Disclaimer**

#### **Forward-Looking Statements**

Any "forward-looking" statements, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, contained herein, including those relating to TriMas' business, financial condition or future results, involve risks and uncertainties with respect to, including, but not limited to: the severity and duration of the ongoing coronavirus ("COVID-19") pandemic on our operations, customers and suppliers, as well as related actions taken by governmental authorities and other third parties in response, each of which is uncertain, rapidly changing and difficult to predict; general economic and currency conditions; inflationary pressures on our supply chain, including raw material and energy costs, and customers; interest rate volatility; risks and uncertainties associated with intangible assets, including goodwill or other intangible asset impairment charges; competitive factors; future trends; our ability to realize our business strategies; our ability to identify attractive acquisition candidates, successfully integrate acquired operations or realize the intended benefits of such acquisitions; information technology and other cyber-related risks; the performance of our subcontractors and suppliers; supply constraints, including the availability and cost of raw materials; market demand; intellectual property factors; litigation; government and regulatory actions, including, without limitation, climate change legislation and other environmental regulations, as well as the impact of tariffs, quotas and surcharges; our leverage; liabilities imposed by our debt instruments; labor disputes and shortages; changes to fiscal and tax policies; contingent liabilities relating to acquisition activities; the disruption of operations from catastrophic or extraordinary events, including natural disasters and public health crises; the amount and timing of future dividends and/or share repurchases, which remain subject to Board approval and depend on market and other conditions; ou


#### **Non-GAAP Financial Measures**

In this presentation, certain non-GAAP financial measures may be used. Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measure may be found in the Appendix at the end of this presentation or in the earnings releases available on the Company's website. Additional information is available at www.trimascorp.com under the "Investors" section.

Please see the Appendix for details regarding certain costs, expenses and other amounts or charges, collectively described as "Special Items," that are included in the determination of net income, earnings per share and/or cash flows from operating activities under GAAP, but that management believes should be separately considered when evaluating the quality of the Company's core operating results, given they may not reflect the ongoing activities of the business. Management believes that presenting these non-GAAP financial measures, by adjusting for Special Items, provides useful information to investors by helping them identify underlying trends in the Company's businesses and facilitating comparisons of performance with prior and future periods. These non-GAAP financial measures should be considered in addition to, and not as a replacement for or superior to, the comparable GAAP financial measures.

### **TriMas Overview**

#### TriMas Delivered First Quarter Results On Plan



# 요구 Advancing TriMas' Strategy

- Q1 2022 performance as planned
- Leveraged TriMas Business Model to navigate through inflationary pressures, demand fluctuations and continued pandemic-related uncertainty
- Continued momentum against our capital allocation strategy:
  - Invested for the future in all of our businesses
  - Funded quarterly dividend, while on track to reduce net shares outstanding by ~2% by year end
  - Successfully completed Intertech acquisition, expanding presence in Life Sciences
- Accelerating Sustainability efforts and transparency

#### **Continued strong balance sheet in place to execute our strategic initiatives**

#### **TriMas**

### **TriMas' Value Drivers**



# Packaging at Our Core

- Products that help fight the spread of germs
- Innovation pipeline to drive long-term growth
- Expanding into Life Sciences

#### M&A Augmented Growth

- Expanding Packaging and Aerospace platforms
- Continuously assessing business and product line additions

רך רר ארך

#### Market Recoveries

- Well positioned as aerospace markets rebound
- Expect margin leverage due to previous realignment actions



#### Treasury Actions

- Proactively managing strong balance sheet
- Momentum in returning capital to investors through share buybacks and quarterly dividends



#### Commitment to ESG

- Operating TriMas in a way to positively benefit society
- Enhancing transparency and communications on our ESG progress

#### Multiple pathways for shareholders to win with TriMas

### **TriMas Packaging Overview**





- TriMas' highest priority growth platform
  - Organic growth of GDP+
  - Augmented by complementary acquisitions in targeted end markets
- Driving growth through:
  - Innovative new products and sustainable solutions
  - Expansion in higher-growth and resilient end markets
  - Leveraging global customer relationships and product offering
- Future performance improvement via:
  - TriMas Business Model and Kaizen culture
  - Continued focus on integrating acquisitions
  - Supply chain management and optimization of global, flexible footprint

#### **2021 Sales** (Pro forma for recent acquisitions)

#### By End Market



TriMas

#### We continue to invest in our future.

### **Recent Acquisitions – Life Sciences**

Further Expands Our Offerings into Life Sciences Market



- Specializes in custom injection molding for products used in medical applications, as well as consumer and industrial applications
  - Highly-engineered and tight tolerance components used in vascular access and in vitro diagnostic applications
  - Dedicated MedAccred<sup>®</sup> facility and Class 8 controlled environment
  - Manufactures injection-molded products for food, wellness, hospitality and e-commerce logistics applications in a separate facility
  - Innovative and advanced R&D testing of biodegradable polymers
- Generated ~\$32 million in revenue in FY 2021



- Manufactures custom components and devices for drug delivery, diagnostic and orthopedic medical applications
  - Advanced in-house tool making capabilities
  - ISO 13485 certified injection molding facility
  - ISO Class 8 clean room
  - Rapid prototyping to enhance speed-to-market advantage on innovation and new product designs
- Generated ~\$18 million in revenue in FY 2021









#### Further expands our offerings in attractive Life Sciences end markets

### **First Quarter Results**



### **First Quarter 2022 Results**

Adjusted for Special Items	Q1 2022	Q1 2021
Net Sales	\$224.3	\$206.7
Operating Profit	\$26.2	\$26.6
Operating Profit Margin	11.7%	12.9%
Net Income	\$17.6	\$17.4
Adjusted Earnings Per Share <sup>(1)</sup>	\$0.50	\$0.49
Adjusted EBITDA <sup>(2)</sup>	\$42.3	\$40.6
Adjusted EBITDA Margin	18.9%	19.6%



#### Q1 2022 Results

- Sales increased 8.5% primarily due to robust organic growth in our Specialty Products segment and recent acquisitions
- Operating profit was impacted by higher energy costs, pandemic-related labor inefficiencies and a less favorable product sales mix
- Net income increased as the Company benefitted from lower interest and other expense
- Achieved Q1 Adjusted Diluted EPS of \$0.50, in line with Company expectations
- Q1 Adjusted EBITDA<sup>(1)</sup> increased by 4.3%, ending March 31, 2022 with LTM Adjusted EBITDA of \$173.8 million, or ~20% of sales

#### Continuing to drive TriMas' momentum

Note: All items are adjusted for Special Items. Please see the Appendix for a detailed reconciliation to GAAP results. Unaudited, dollars in millions, except per share amounts.
(1) Adjusted EBITDA is defined as net income (loss) operations plus expense (benefit) for interest, taxes, depreciation, amortization and non-cash stock compensation, all as adjusted for the impact of Special Items.



### **Strong Balance Sheet and Cash Flow**

Key Credit Statistics	March 31, 2022	March 31, 2021
Total Debt	\$394.0	\$690.2
Less: Cash	\$58.8	\$421.1
Net Debt	\$335.2	\$269.1
LTM Adjusted EBITDA <sup>(1)</sup>	\$173.8	\$162.0
Net Leverage <sup>(2)</sup>	1.9x	1.7x
Q1 Free Cash Flow <sup>(3)</sup>	(\$1.9)	\$10.3

# Strong annual cash flow and liquidity to invest in our strategic initiatives

- Q1 2022 Free Cash Flow<sup>(3)</sup> as expected and reflects proactive management of inventory in response to global supply chain challenges
- Net Leverage<sup>(2)</sup> below long range target of 2.0x, even after acquisitions, dividends and share repurchases
- Capital structure and expected performance enables forecasted 2022 FCF to be > 100% of net income

Tr Mas

#### Continue to tightly manage balance sheet while executing growth plan

Note: All items are adjusted for Special Items. Please see the Appendix for a detailed reconciliation to GAAP results. Unaudited, dollars in millions.

(1) Adjusted EBITDA is defined as net income (loss) plus expense (benefit) for interest, taxes, depreciation, amortization and non-cash stock compensation, all as adjusted for the impact of Special Items.

(2) Net Leverage is defined as Net Debt/LTM Adjusted EBITDA

(3) Free Cash Flow is defined as Net Cash Provided by/(Used for) Operating Activities from continuing operations, excluding the cash impact of Special Items, less capital expenditures

### **TriMas Packaging Segment**

# P

#### **Results & Forward Perspective**

Adjusted for Special Items	Q1 2022	Q1 2021
Net Sales	\$138.5	\$132.1
Operating Profit	\$23.8	\$23.6
Operating Margin	17.2%	17.9%
Adjusted EBITDA <sup>(1)</sup>	\$31.8	\$31.0
Adjusted EBITDA Margin	23.0%	23.5%

#### **Quarterly Takeaways**

- Sales increased 4.8% as acquisition-related sales and higher demand for food & beverage and industrial & agricultural applications were partially offset by the planned abatement of high levels of pandemic-related demand in Q1 2021 and unfavorable currency
- Operating profit remained relatively flat as the impact of increased sales was offset by higher energy costs
- Completed the Intertech acquisition during Q1, further expanding our precision injection molding capabilities into Life Sciences applications

#### **Forward Perspective**

- Expect organic sales increase augmented by acquisitions
- Outlook assumes stabilization of key material costs in 2022, with added inflationary pressure on certain labor and production costs
- Less favorable product sales mix related to acquisitions in near-term



### **TriMas Aerospace Segment**

#### **Results & Forward Perspective**

Adjusted for Special Items	Q1 2022	Q1 2021
Net Sales	\$44.5	\$44.6
Operating Profit	\$2.4	\$5.0
Operating Margin	5.4%	11.1%
Adjusted EBITDA <sup>(1)</sup>	\$7.2	\$9.5
Adjusted EBITDA Margin	16.3%	21.4%

#### **Quarterly Takeaways**

- Sales were relatively flat as the impact of new business awards and acquisition-related sales were offset by the planned decline in special stocking orders, which were predominantly fulfilled in 2021
- Operating profit decreased as a result of a less favorable sales mix from lower levels of stocking orders, and further labor inefficiencies related to the pandemic
- Continue to focus on positioning TriMas Aerospace for further recovery as air travel increases and commercial jet production rebounds



#### **Forward Perspective**

- Sales growth from new business awards, the expected start of a market recovery and acquisitions more than offset the impact of the 2021 special stocking orders
- Normalizing for stocking orders, 2022 sales growth would be ~20%
- Margin range reflects product mix and anticipated inflationary pressures on input costs and labor



### **TriMas Specialty Products Segment**



#### **Results & Forward Perspective**

Adjusted for Special Items	Q1 2022	Q1 2021
Net Sales	\$41.3	\$30.0
Operating Profit	\$7.2	\$4.5
Operating Margin	17.5%	15.1%
Adjusted EBITDA <sup>(1)</sup>	\$8.3	\$5.5
Adjusted EBITDA Margin	20.2%	18.3%

#### **Quarterly Takeaways**

- Sales increased 37.5% as a result of strong demand for steel cylinders and increased demand for parts for remote power generation activity
- Operating profit and the related margin increased as a result of leveraging previous factory floor improvement actions and higher sales from increased demand
- Current backlog and near-term order intake for steel cylinders remains at high levels



#### **Forward Perspective**

- Continued market demand recovery expected to drive sales increases
- Continue to make investments in process and product innovation, as well as improvements to accelerate core Specialty Products growth
- Norris Cylinder, which has been designated a "Made in the USA" manufacturer, is positioned well as the only steel cylinder manufacturer in North America





## **Outlook & Summary**



### **Forward Expectations – Reaffirmed Outlook**

As of April 28, 2022

#### FY 2022 Outlook



- Organic sales growth expected to be augmented by acquisitions; more than overcoming TriMas Aerospace special stocking orders fulfilled in 2021
- Normalizing for 2021 Aerospace special stocking orders, 2022 Adjusted EPS midpoint represents an increase of ~15%

#### **Continuing to Invest for our Future**



TriMas Packaging New Albany, Ohio, Facility Progress

#### **Company reaffirms FY 2022 Outlook**

Sales growth as compared to FY 2021.

Note: All of the figures on this slide are adjusted for any current and future Special Items. Adjusted EPS is defined as diluted EPS per GAAP plus or minus the after tax impact of Special Items and acquisition-related intangible amortization expense. See Appendix for reconciliation between GAAP and Adjusted Diluted EPS outlook.

Free Cash Flow is defined as Net Cash Provided by/(Used for) Operating Activities, excluding the cash impact of Special Items, less capital expenditures.



**TriMas Q&A** 



**Strong Brand Names** 

**Diverse End Markets** 

**Innovative Product Solutions** 



# Appendix



### **Condensed Consolidated Balance Sheet**

	N	March 31, 2022	De	cember 31, 2021
	(1	unaudited)		
Assets				
Current assets:				
Cash and cash equivalents	\$	58,820	\$	140,740
Receivables, net		150,500		125,630
Inventories		158,360		152,450
Prepaid expenses and other current assets		16,290		12,950
Total current assets		383,970		431,770
Property and equipment, net		279,840		265,630
Operating lease right-of-use assets		53,150		50,650
Goodwill		345,010		315,490
Other intangibles, net		204,260		196,730
Deferred income taxes		7,920		9,740
Other assets		34,900		33,630
Total assets	\$	1,309,050	\$	1,303,640
Liabilities and Shareholders' Equity				
Current liabilities:				
Accounts payable	\$	94,870	\$	87,800
Accrued liabilities		51,560		58,980
Operating lease liabilities, current portion		8,400		8,120
Total current liabilities	_	154,830		154,900
Long-term debt, net		394,040		393,820
Operating lease liabilities		46,390		43,780
Deferred income taxes		22,460		21,260
Other long-term liabilities		57,500		59,030
Total liabilities		675,220		672,790
Total shareholders' equity		633,830		630,850
Total liabilities and shareholders' equity	\$	1,309,050	\$	1,303,640

### **Consolidated Statement of Operations**

		nths ended ch 31,
	2022	2021
	(unal	ıdited)
Net sales	\$ 224,310	\$ 206,730
Cost of sales	(170,600)	(155,400)
Gross profit	53,710	51,330
Selling, general and administrative expenses	(31,780)	(30,220)
Operating profit	21,930	21,110
Other expense, net:		
Interest expense	(3,410)	(3,550)
Debt financing and related expenses	-	(200)
Other income (expense), net	(280)	(930)
Other expense, net	(3,690)	(4,680)
Income before income tax expense	18,240	16,430
Income tax expense	(4,070)	(3,370)
Net income	<u>\$ 14,170</u>	\$ 13,060
Earnings per share - basic:		
Net income per share	\$ 0.33	\$ 0.30
Weighted average common shares - basic	42,799,206	43,185,007
Earnings per share - diluted:		
Net income per share	\$ 0.33	\$ 0.30
Weighted average common shares - diluted	43,109,693	43,634,876

### **Consolidated Statement of Cash Flows**

	 Three months ended March 31,		
	2022		2021
Cash Flows from Operating Activities:			
Net income	\$ 14,170	\$	13,060
Adjustments to reconcile net income to net cash provided by operating activities, net of			
acquisition impact:			
Loss on dispositions of assets	20		20
Depreciation	8,470		7,850
Amortization of intangible assets	5,290		5,390
Amortization of debt issue costs	220		300
Deferred income taxes	3,000		2,200
Non-cash compensation expense	2,820		2,440
Debt financing and related expenses	-		200
Increase in receivables	(22,330)		(15,640)
Increase in inventories	(910)		(3,110)
Increase in prepaid expenses and other assets	(680)		(2,070)
Increase (decrease) in accounts payable and accrued liabilities	(5,210)		1,950
Other operating activities	810		3,150
Net cash provided by operating activities, net of acquisition impact	 5,670		15,740
Cash Flows from Investing Activities:			
Capital expenditures	(11,890)		(9,370)
Acquisition of businesses, net of cash acquired	(63,950)		-
Net proceeds from disposition of property and equipment	20		-
Net cash used for investing activities	 (75,820)		(9,370)
Cash Flows from Financing Activities:			
Proceeds from issuance of senior notes	-		400,000
Repayments of borrowings on revolving credit facilities	-		(48,620)
Debt financing fees	-		(6,150
Payments to purchase common stock	(9,060)		(2,640)
Shares surrendered upon exercise and vesting of equity awards to cover taxes	(970)		(1,770)
Dividends paid	(1,740)		-
Net cash provided by (used for) financing activities	 (11,770)		340,820
Cash and Cash Equivalents:			
Increase (decrease) for the period	(81,920)		347,190
At beginning of period	140,740		73,950
At end of period	\$ 58,820	\$	421,140
Supplemental disclosure of cash flow information:			
Cash paid for interest	\$ 310	\$	520
Cash paid for taxes	\$ 620	\$	1.160

### **Company and Segment Financial Information**

	Three months ended March 31,			
		2022		2021
Packaging				
Net sales	\$	138,490	\$	132,090
Operating profit	\$	21,330	\$	21,300
Special Items to consider in evaluating operating profit:				
Purchase accounting costs		480		830
Business restructuring and severance costs		1,970		1,510
Adjusted operating profit	\$	23,780	\$	23,640
Aerospace				
Net sales	\$	44,520	\$	44,610
Operating profit	\$	1,840	\$	4,500
Special Items to consider in evaluating operating profit:				
Purchase accounting costs		240		-
Business restructuring and severance costs		330		450
Adjusted operating profit	\$	2,410	\$	4,950
Specialty Products				
Net sales	\$	41,300	\$	30,030
Operating profit	\$	7,240	\$	4,520
Corporate Expenses				
Operating loss	\$	(8,480)	\$	(9,210)
Special Items to consider in evaluating operating loss:				
M&A diligence and transaction costs		910		490
Business restructuring and severance costs		370		2,250
Adjusted operating loss	\$	(7,200)	\$	(6,470)
Total Company				
Net sales	\$	224,310	\$	206,730
Operating profit	\$	21,930	\$	21,110
Total Special Items to consider in evaluating operating profit	-	4,300	-	5,530
Adjusted operating profit	\$	26,230	\$	26,640

YOY Growth %						
	Organic	Acquisitions	Fx	Total		
Q1 2022 vs. Q1 202	21					
Consolidated TriMas	5.3%	4.3%	-1.1%	8.5%		
Packaging	0.8%	5.8%	-1.8%	4.8%		
Aerospace	-3.3%	3.1%		-0.2%		
Specialty Products	37.5%			37.5%		

### **Additional Information on Non-GAAP Measures**

		Three mon Marc	thse h31,		
		2022		2021	
Net income, as reported	\$	14,170	\$	13,060	
Special Items to consider in evaluating quality of net income:					
Business restructuring and severance costs		2,820		4,210	
M&A diligence and transaction costs		910		490	
Purchase accounting costs		720		830	
Debt financing and related expenses		-		200	
Income tax effect of Special Items <sup>(1)</sup>		(1,050)		(1,390	
Adjusted net income	\$	17,570	\$	17,400	
			onths ended ch 31,		
	-	2022	,	2021	
Diluted earnings per share, as reported	\$		\$		
Diluted earnings per share, as reported Special Items to consider in evaluating quality of diluted EPS:		2022	\$		
		2022	\$	0.30	
Special Items to consider in evaluating quality of diluted EPS: Business restructuring and severance costs M&A diligence and transaction costs		2022 0.33	\$	0.30	
Special Items to consider in evaluating quality of diluted EPS: Business restructuring and severance costs M&A diligence and transaction costs Purchase accounting costs		2022 0.33 0.06	\$	0.30 0.10 0.01	
Special Items to consider in evaluating quality of diluted EPS: Business restructuring and severance costs M&A diligence and transaction costs Purchase accounting costs Debt financing and related expenses		2022 0.33 0.06 0.02	\$	0.30 0.10 0.01	
Special Items to consider in evaluating quality of diluted EPS: Business restructuring and severance costs M&A diligence and transaction costs Purchase accounting costs		2022 0.33 0.06 0.02	\$	0.30 0.10 0.01 0.02	
Special Items to consider in evaluating quality of diluted EPS: Business restructuring and severance costs M&A diligence and transaction costs Purchase accounting costs Debt financing and related expenses		2022 0.33 0.06 0.02 0.02 -	\$	0.30 0.10 0.01 0.02 - (0.03	
Special Items to consider in evaluating quality of diluted EPS: Business restructuring and severance costs M&A diligence and transaction costs Purchase accounting costs Debt financing and related expenses Income tax effect of Special Items <sup>(1)</sup>		2022 0.33 0.06 0.02 0.02 - (0.02)	\$	2021 0.30 0.10 0.01 0.02 - (0.03 0.12 (0.03	
Special Items to consider in evaluating quality of diluted EPS: Business restructuring and severance costs M&A diligence and transaction costs Purchase accounting costs Debt financing and related expenses Income tax effect of Special Items <sup>(1)</sup> Pre-tax amortization of acquisition-related intangible assets		2022 0.33 0.06 0.02 0.02 - (0.02) 0.12	\$	0.30 0.10 0.02 - (0.03 0.12	

<sup>(1)</sup> Income tax effect of Special Items and amortization of acquisition-related intangible assets is calculated on an item-byitem basis, utilizing the tax rate in the jurisdiction where the Special Item or amortization occurred. For the three month periods ended March 31, 2022, and 2021, the income tax effect of Special Items varied from the tax rate inherent in the Company's reported GAAP results, primarily as a result of certain discrete items that occurred during the period for GAAP reporting purposes.

	Three months ended March 31,			
	2022		2021	
Adjusted operating profit	\$ 26,230	\$	26,640	
Corporate operating expenses (adjusted)	4,560		4,520	
Non-cash stock compensation (adjusted)	2,450		1,610	
Legacy expenses	190		340	
Corporate expenses	7,200		6,470	
Adjusted segment operating profit	\$ 33,430	\$	33,110	
Adjusted segment operating profit margin	14.9%		16.0%	

### **Additional Information on Non-GAAP Measures**

		Three months ended March 31,										
		2022				2021						
	As	reported	Spec	ial Items	As	adjusted	As	reported	Spec	ial Items	As	adjusted
Net cash provided by operating activities	\$	5,670	\$	4,310	\$	9,980	\$	15,740	\$	3,920	\$	19,660
Less: Capital expenditures		(11,890)		-		(11,890)		(9,370)		-		(9,370)
Free Cash Flow		(6,220)		4,310		(1,910)		6,370		3,920		10,290
Net income		14,170		3,400		17,570		13,060		4,340		17,400
Free Cash Flow as a percentage of net income	-	-44%				-11%		49%				59%

	N	March 31, 2022		December 31, 2021		March 31, 2021	
Current portion, long-term debt	\$	-	\$	-	\$	300,000	
Long-term debt, net		394,040		393,820		390,190	
Total Debt		394,040		393,820		690,190	
Less: Cash and cash equivalents		58,820		140,740		421,140	
Net Debt	\$	335,220	\$	253,080	\$	269,050	



### **Additional Information on Non-GAAP Measures**

	Three months ended March 31,			Twelve months ended March 31,				
		2022		2021		2022		2021
Net income (loss), as reported	\$	14,170	\$	13,060	\$	58,420	\$	(79,820)
Depreciation expense		8,470		7,850		32,510		30,210
Amortization expense		5,290		5,390		21,460		21,290
Interest expense		3,410		3,550		14,370		14,630
Income tax expense (benefit)		4,070		3,370		12,500		(22,630)
Non-cash compensation expense		2,820		2,440		9,880		8,670
Adjusted EBITDA, before Special Items	\$	38,230	\$	35,660	\$	149,140	\$	(27,650)
Adjusted EBITDA impact of Special Items		4,080		4,900		24,610		189,650
Adjusted EBITDA <sup>(1)</sup>	\$	42,310	\$	40,560	\$	173,750	\$	162,000
Adjusted EBITDA as a percentage of net sales		18.9%		19.6%		19.9%		20.4%
Packaging	\$	31,790	\$	31,000	\$	132,340	\$	130,760
Aerospace		7,240		9,540		31,940		31,540
Specialty Products		8,340		5,500		29,520		18,980
Segment Adjusted EBITDA <sup>(1)</sup>	\$	47,370	\$	46,040	\$	193,800	\$	181,280
Segment Adjusted EBITDA as a percentage of net sales		21.1%		22.3%		22.2%		22.8%
Other Corporate expenses		(5,060)		(5,480)		(20,050)		(19,280)
Adjusted EBITDA <sup>(1)</sup>	\$	42,310	\$	40,560	\$	173,750	\$	162,000

23

### **Addition Information on Non-GAAP Measures**

#### As of April 28, 2022

#### Full Year 2021 GAAP to Non-GAAP EPS Outlook Reconciliation

	Twelve months ended December 31, 2022			
	Low		High	
Diluted earnings per share (GAAP)	\$ 1.82	\$	1.92	
Pre-tax amortization of acquisition-related intangible assets <sup>(1)</sup>	0.46		0.46	
Income tax benefit on amortization of acquisition-related intangible assets	(0.11)		(0.11)	
Impact of Special Items <sup>(2)</sup>	 0.08		0.08	
Adjusted diluted earnings per share	\$ 2.25	\$	2.35	

(1) These amounts relate to acquisitions completed prior to March 31, 2022. The Company is unable to provide forward-looking estimates of future acquisitions, if any, that have not yet been consummated.

(2) The Company is unable to provide forward-looking estimates of Special Items without unreasonable effort, due to the uncertainty and inherent difficulty of predicting the occurrence and the financial impact of such items and the periods in which such items may be recognized. For the same reasons, the Company is unable to address the probable significance of the unavailable information, which could be material to future results.



24

### Fiscal Year 2022 Outlook – Additional Assumptions

As of April 28, 2022

#### FY 2022 Full Company Outlook



#### **Enterprise-wide Assumptions**

Effective Tax Rate:	23% to 24%
Capital Expenditures as a % of Sales:	5% to 6%*
Interest Expense:	~\$14M

\*Includes continued investment to launch the new TriMas Packaging facility in Ohio, USA Note: Corporate expenses are expected to be in line with 2021 amounts.

#### FY 2022 Outlook by Segment

TriMas Packaging	
Sales Growth	11% to 14%
Operating Profit Margin %	18.5% to 19.5%
TriMas Aerospace	
Sales Growth	1% to 3%
Operating Profit Margin %	4% to 6%
TriMas Specialty Products	
Sales Growth	8% to 12%
Operating Profit Margin %	16% to 17%

Sales growth as compared to FY 2021.

25

Note: All of the figures on this slide are adjusted for any current and future Special Items. Adjusted EPS is defined as diluted EPS per GAAP plus or minus the after tax impact of Special Items and acquisition-related intangible amortization expense. See Appendix for reconciliation between GAAP and Adjusted Diluted EPS outlook.

